The effect of CCL1 antisense ODN for monocytes from patients with hepatocellular Carcinoma on tumor progression

2016 Fiscal Year Final Research Report

• Project/Area Number: 26860533
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology
• Research Institution: Osaka Medical College
• Principal Investigator: Asai Akira 大阪医科大学, 医学部, 講師 (30622146)
• Research Collaborator: Suzuki Fujio University of Texas Medical Branch, Internal Medicine/Infectious Diseases, Professor
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 単球 / 肝細胞癌 / CCL1

Outline of Final Research Achievements

Despite major advances in curative and palliative approaches, hepatocellular carcinoma (HCC) is still the third leading cause of cancer-related death worldwide. M1 monocytes play a key role in host antitumor defenses in HCC. The majority of monocytes from early HCC stage patients switched to the M1 phenotype (IL-12+IL-10－iNOS+cells), whereas the majority of monocytes from advanced HCC stage patients did not switch to the M1 phenotype and continued to express M2b phenotypic properties (IL-12－IL-10+CCL1+iNOS－cells). Monocytes from advanced HCC stage patients showed M1 polarization after treatment with CCL1 antisense oligodeoxynucleotide (ODN). Therefore, our study indicates that anti-HCC defenses of advanced HCC stage patients may be improved after CCL1 antisense ODN treatment.

Free Research Field

肝臓